Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
Phase 2AcquisitionExecutive Change
Preview
Source: FierceBiotech
Merck sold off its ophthalmology business to Akorn Pharmaceuticals and Japan's Santen in deals in 2013 and 2014, respectively.
Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech.
The deal features $1.3 billion in cash up front and $1.7 billion in potential milestones.
Merck will take on a pipeline of vision loss candidates, including lead asset Restoret, also known as EYE103, which is poised to enter a phase 2b/3 trial for diabetic macular edema (DME). The therapy is a tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway, according to a Wednesday press release.
Restoret has already been tested in a phase 1b/2a trial called AMARONE in DME and neovascular age-related macular degeneration. The phase 2b/3 test is slated to begin in the second half of this year.
Privately held EyeBio emerged just three years ago to advance a retinal disease therapy developed by David Guyer, M.D. He currently serves as CEO and will move over to Merck in the transaction, along with Chief Scientific Officer Tony Adamis, M.D.
Merck sold off part of its ophthalmology business to Akorn Pharmaceuticals in 2013 in a $52.8 million deal that included a handful of approved products. The following year, Merck sold certain rights to its eye drugs to Japan's Santen for $600 million up front.
The pharma giant has made some efforts to build out a portfolio in eye diseases more recently. However, the journey through the clinic has been difficult. The New Jersey pharma walked away from the bulk of a partnership with NGM Biopharmaceuticals in 2022 after a phase 2 failure. The companies had been developing NGM621, an anti-complement C3 antibody being trialed in patients with an eye degenerative disease called geographic atrophy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.